Anika Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Anika Therapeutics, Inc. (ANIK) reported Other Comprehensive Income (Loss), Net of Tax of -$19.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-29
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$19.00K, a 101.41% decline year-over-year.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$351.00K, a 151.62% decline year-over-year.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$184.00K, a 125.73% decline year-over-year.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $1.35M.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $1.82M.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$840.00K, a 268.00% decline from fiscal 2023.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $500.00K.
- Anika Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$725.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$19.00K 10-Q · filed 2026-07-29 | -$370.00K derived: sum of 2 quarters · filed 2026-07-29 | |||
| 2026-03-31 | -$351.00K 10-Q · filed 2026-07-29 | ||||
| 2025-12-31 | $1.82M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$184.00K 10-Q · filed 2025-11-05 | $1.16M derived: sum of 2 quarters · filed 2026-07-29 | $1.84M derived: sum of 3 quarters · filed 2026-07-29 | ||
| 2025-06-30 | $1.35M 10-Q · filed 2026-07-29 | $2.03M derived: sum of 2 quarters · filed 2026-07-29 | |||
| 2025-03-31 | $680.00K 10-Q · filed 2026-07-29 | ||||
| 2024-12-31 | -$840.00K 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $715.00K 10-Q · filed 2025-11-05 | $614.00K derived: sum of 2 quarters · filed 2025-11-05 | $242.00K derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$101.00K 10-Q · filed 2025-11-05 | -$473.00K derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-31 | -$372.00K 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $500.00K 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | -$407.00K 10-Q · filed 2024-11-04 | -$393.00K derived: sum of 2 quarters · filed 2024-11-04 | -$121.00K derived: sum of 3 quarters · filed 2024-11-04 | ||
| 2023-06-30 | $14.00K 10-Q · filed 2024-11-04 | $286.00K derived: sum of 2 quarters · filed 2024-11-04 | |||
| 2023-03-31 | $272.00K 10-Q · filed 2024-11-04 | ||||
| 2022-12-31 | -$725.00K 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | -$851.00K 10-Q · filed 2023-11-03 | -$1.70M derived: sum of 2 quarters · filed 2023-11-03 | -$1.78M derived: sum of 3 quarters · filed 2023-11-03 | ||
| 2022-06-30 | -$847.00K 10-Q · filed 2023-11-03 | -$928.00K derived: sum of 2 quarters · filed 2023-11-03 | |||
| 2022-03-31 | -$81.00K 10-Q · filed 2023-11-03 | ||||
| 2021-12-31 | -$1.18M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | -$467.00K 10-Q · filed 2022-11-09 | -$268.00K derived: sum of 2 quarters · filed 2022-11-09 | -$777.00K derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $199.00K 10-Q · filed 2022-11-09 | -$310.00K derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | -$509.00K 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $1.36M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $522.00K 10-Q · filed 2021-11-05 | $731.00K derived: sum of 2 quarters · filed 2021-11-05 | $602.00K derived: sum of 3 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $209.00K 10-Q · filed 2021-11-05 | $80.00K derived: sum of 2 quarters · filed 2021-11-05 | |||
| 2020-03-31 | -$129.00K 10-Q · filed 2021-11-05 | ||||
| 2019-12-31 | -$372.00K 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | -$622.00K 10-Q · filed 2020-11-05 | -$477.00K derived: sum of 2 quarters · filed 2020-11-05 | -$792.00K derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $145.00K 10-Q · filed 2020-11-05 | -$170.00K derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | -$315.00K 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | -$742.00K 10-K/A · filed 2021-04-26 | ||||
| 2018-09-30 | -$113.00K 10-Q · filed 2019-10-28 | -$1.06M derived: sum of 2 quarters · filed 2019-10-28 | -$444.00K derived: sum of 3 quarters · filed 2019-10-28 | ||
| 2018-06-30 | -$951.00K 10-Q · filed 2019-10-28 | -$331.00K derived: sum of 2 quarters · filed 2019-10-28 | |||
| 2018-03-31 | $620.00K 10-Q · filed 2019-10-28 | ||||
| 2017-12-31 | $2.53M 10-K · filed 2020-03-06 | ||||
| 2016-12-31 | -$668.00K 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | -$2.15M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | -$899.61K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | -$2.58M derived: sum of 2 quarters · filed 2017-02-24 | -$2.80M 10-K · filed 2017-02-24 | -$2.80M 10-K · filed 2015-03-13 | |
| 2014-09-30 | -$1.68M 10-Q · filed 2014-11-06 | -$1.90M 10-Q · filed 2014-11-06 | |||
| 2013-12-31 | $448.88K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $1.37M derived: sum of 2 quarters · filed 2016-03-10 | $956.00K 10-K · filed 2016-03-10 | $955.53K 10-K · filed 2014-03-13 | |
| 2013-09-30 | $916.47K 10-Q · filed 2014-11-06 | $507.12K 10-Q · filed 2014-11-06 | |||
| 2012-12-31 | $412.55K 10-K · filed 2015-03-13 | ||||
| 2011-12-31 | -$519.40K 10-K · filed 2014-03-13 | ||||
| 2010-12-31 | -$2.55M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |